Department of Neurology, Second Affiliated Hospital of Chongqing Medical University , Chongqing, China.
Department of Neurology, Zigong First People's Hospital , Sichuan, China.
Neurol Res. 2021 Mar;43(3):220-224. doi: 10.1080/01616412.2020.1839690. Epub 2020 Dec 4.
Tirofiban can be used to treat patients with acute ischemic stroke (AIS), this study was to evaluate the efficacy and safety of tirofiban combined with heparin in the treatment of mild to moderate AIS. A total of 98 patients with mild to moderate AIS randomly were divided into 2 groups within 48 h: the treatment group treated with tirofiban and, and the control group treated with aspirin + clopidogrel. The treatment group was given the same scheme as the control group after the treatment of tirofiban combined with heparin for 48 h. It was found that, compared with the control group, a significant decreased National Institute of Health stroke scale (NIHSS) was found in 48 h and 14 d, especially to the Barthel index (BI) in the treatment group (P < 0.05). Furthermore, Modified Rankin Scale (MRS, ≤2) in the treatment group was significantly upregulated in 90 d (P < 0.05). However, there were no significant differences in the adverse drug reactions between the two groups. It was indicated that nerve function and long-term prognosis in patients undergoing heparin for mild to moderate AIS were obviously improved than the control group.
替罗非班可用于治疗急性缺血性脑卒中（AIS）患者，本研究旨在评估替罗非班联合肝素治疗轻中度 AIS 的疗效和安全性。98 例轻中度 AIS 患者在发病 48 小时内随机分为两组：治疗组给予替罗非班治疗，对照组给予阿司匹林+氯吡格雷治疗。替罗非班联合肝素治疗 48 小时后，治疗组给予与对照组相同的方案。结果发现，与对照组相比，治疗组在 48 小时和 14 天的 NIHSS 评分明显降低，尤其是治疗组的 Barthel 指数（BI）（P<0.05）。此外，治疗组在 90 天的改良 Rankin 量表（MRS，≤2）明显上调（P<0.05）。然而，两组不良反应无明显差异。结果表明，肝素治疗轻中度 AIS 患者的神经功能和长期预后明显优于对照组。
